Biotech News
Related news
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
LEGNLegend Biotech Corporation2026-09-01 12:00 EST
Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference
REPLReplimune Group2026-09-03 12:00 EST
Replimune to Present at the Cantor Global Healthcare Conference 2026
ACRVAcrivon Therapeutics2026-09-02 12:00 EST
Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference
LYELLyell Immunopharma2026-09-14 11:00 EST
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
FATEFate Therapeutics2026-09-03 11:00 EST
Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference
PRLDPrelude Therapeutics2026-09-11 11:01 EST
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
MGNXMacroGenics2026-09-09 20:05 EST
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
FATEFate Therapeutics2026-09-09 11:00 EST
Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-09-10 12:00 EST
Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium
ERASErasca2026-09-08 11:00 EST
Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
ERASErasca2026-08-24 12:00 EST
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
ERASErasca2026-08-11 20:01 EST
Erasca Reports Second Quarter 2026 Business Updates and Financial Results
ERASErasca2026-08-10 20:01 EST
Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stock data
- Close
- 14.30 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States